Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model
- PMID: 25583102
- DOI: 10.1016/j.jaci.2014.11.028
Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model
Abstract
Background: Allergy to cow's milk increases the risk of sensitization to other foods in young children.
Objectives: We sought to evaluate the effect of early epicutaneous immunotherapy (EPIT) on further sensitization to peanut or house dust mite (HDM) in a murine model of sensitization to cow's milk.
Methods: BALB/c mice orally sensitized to milk were epicutaneously treated with a Viaskin patch (DBV Technologies) loaded with milk proteins for 8 weeks. Mice were then sensitized to peanut or HDM. After sensitization to peanut, mice were exposed to a peanut regimen known to induce eosinophilic esophageal inflammation. After sensitization to HDM, mice were challenged with aerosols to HDM, and airway hyperresponsiveness was evaluated by using plethysmography. Humoral response was also analyzed. The role of regulatory T (Treg) cells was evaluated by adoptively transferring Treg cells from milk EPIT-treated mice to naive mice before sensitization to peanut. Protection against anaphylaxis was also investigated. Methylation of the promoter region of transcription factors was analyzed by using PCR assays.
Results: In milk-sensitized mice specific EPIT prevented further sensitization to peanut or HDM. EPIT significantly modified the humoral response, reduced TH2 cytokine levels, decreased eosinophilic esophageal infiltration, and suppressed airway hyperresponsiveness. The protective effect was sustained over 2 months. Moreover, the adoptive transfer of milk EPIT Treg cells completely prevented sensitization to peanut and peanut-induced anaphylaxis. Milk EPIT enhanced methylation of the GATA-3 promoter region.
Conclusions: Our results showed that EPIT influences the natural history of allergy and reduces the risk of further sensitization through a Treg cell-dependent mechanism.
Keywords: Allergy; epicutaneous immunotherapy; food allergy; milk; peanut; prevention; treatment.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy.Clin Exp Allergy. 2010 Apr;40(4):659-67. doi: 10.1111/j.1365-2222.2009.03430.x. Epub 2009 Dec 10. Clin Exp Allergy. 2010. PMID: 20002446
-
The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice.Clin Exp Allergy. 2014 Jun;44(6):867-81. doi: 10.1111/cea.12312. Clin Exp Allergy. 2014. PMID: 24666588 Free PMC article.
-
Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice.Allergy. 2019 Jan;74(1):152-164. doi: 10.1111/all.13479. Epub 2018 Oct 8. Allergy. 2019. PMID: 29779209 Free PMC article.
-
The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review.Clin Rev Allergy Immunol. 2018 Oct;55(2):153-161. doi: 10.1007/s12016-017-8650-3. Clin Rev Allergy Immunol. 2018. PMID: 29081025 Review.
-
Epicutaneous peanut patch device for the treatment of peanut allergy.Expert Rev Clin Immunol. 2019 May;15(5):449-460. doi: 10.1080/1744666X.2019.1593138. Epub 2019 Mar 27. Expert Rev Clin Immunol. 2019. PMID: 30864861 Review.
Cited by
-
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow's Milk Allergy: A Randomized Clinical Trial.JAMA Pediatr. 2024 Feb 26:e236630. doi: 10.1001/jamapediatrics.2023.6630. Online ahead of print. JAMA Pediatr. 2024. PMID: 38407859 Free PMC article.
-
Sustained antigens delivery using composite microneedles for effective epicutaneous immunotherapy.Drug Deliv Transl Res. 2023 Jun;13(6):1828-1841. doi: 10.1007/s13346-023-01298-8. Epub 2023 Mar 24. Drug Deliv Transl Res. 2023. PMID: 36964440
-
Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development.Yonsei Med J. 2022 Oct;63(10):881-891. doi: 10.3349/ymj.2022.0092. Yonsei Med J. 2022. PMID: 36168240 Free PMC article. Review.
-
Th2A cells: The pathogenic players in allergic diseases.Front Immunol. 2022 Aug 8;13:916778. doi: 10.3389/fimmu.2022.916778. eCollection 2022. Front Immunol. 2022. PMID: 36003397 Free PMC article. Review.
-
Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?Front Allergy. 2021 Oct 28;2:747323. doi: 10.3389/falgy.2021.747323. eCollection 2021. Front Allergy. 2021. PMID: 35387059 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
